About Gilead Sciences, Inc
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404
Gilead Sciences, Inc News and around…
Latest news about Gilead Sciences, Inc (GILD) common stock and company :
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The approval of this supplemental New Drug Application (sNDA) expands the indication for Biktarvy to include younger children living with HIV-1 infection and will help to close the gap between HIV treatment options available for adults and children.
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
These two novel-drug makers could be top takeover targets next year.
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.
In this article, we will discuss the top 10 stock picks of James Morrow’s Callodine Capital. If you want to skip our detailed analysis of Morrow’s history, investment philosophy, and hedge fund performance, go directly to James Morrow’s Callodine Capital Portfolio: Top 5 Picks. Callodine Capital Management is the investment arm of the Callodine Group, […]
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease. The final European Commission decision on the Marketing Authorization Application for sacituzumab govitecan is anticipated later in 2021.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2021 financial results will be released on Thursday, October 28, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2021 financial results and will provide a business update.
Dr. Stella Safo, NYC-based HIV Primary Care Physician, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Whirlpool Corp (WHR), where a total volume of 7,196 contracts has been traded thus far today, a contract volume which is representative of approximately 719,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 117.9% of WHR's average daily trading volume over the past month, of 610,200 shares..
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Symbols mentioned in this story: IBB, GILD, REGN, ILMN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy ...
A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. Large...
Dr. Rishi Desai, Chief Medical Officer at Osmosis & Former Center for Disease Control and Prevention Epidemic Intelligence Officer, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
Dr. Ali Raja, Professor at Harvard Medical School, joins Yahoo Finance Live to discuss the latest in the coronavirus pandemic.
Taylor McKay, a senior at Florida A&M University, always knew she wanted to become a surgeon. But it wasn’t until she did an internship with TOUCH: The Black Breast Cancer Alliance, that she decide...
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, ...
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB has been down over 10% for the past 30 days.
Dr. Payal Patel, Infectious Diseases Physician, University of Michigan, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna has a host of vaccines in its pipeline, including against cancer and HIV. It's not a one-trick pony. The post Moderna Stock Looks Fully Valued Here, But It Has a Great Future appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
In this article, we discuss the 10 best big pharma stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Big Pharma Stocks to Buy Now. On September 9, the United States Department of Health and Human Services (HHS) unveiled a comprehensive plan to reduce drug […]
Dr. Steven McDonald, Emergency Medicine Physician, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Dr. Jeremy Faust, Emergency Medicine Physician, Brigham and Women’s Hospital, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
The Zacks Analyst Blog Highlights: Apple, Mastercard, Verizon, Target and Gilead Sciences
Merck is ready to apply for authorization ahead of Pfizer.
A new study shows it is highly effective in preventing deaths if taken early.
The best answer, for now, is maybe.